Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients
- 494 Downloads
Acute skin toxicity is a frequent finding during combined radiotherapy and chemotherapy in head and neck cancer patients. Its timely and appropriate management is crucial for both oncological results and patient’s global quality of life. We herein report clinical data on the use of Hypericum perforatum and neem oil in the treatment of acute skin toxicity during concurrent chemo-radiation for head and neck cancer. A consecutive series of 50 head and neck cancer patients undergoing concomitant radio-chemotherapy with weekly cisplatin was analyzed. Treatment with Hypericum perforatum and neem oil was started in case of G2 acute skin toxicity according to the RTOG/EORTC scoring scale and continued during the whole treatment course and thereafter until complete recovery. The maximum detected acute skin toxicity included Grade 2 events in 62% of cases and G3 in 32% during treatment and G2 and G3 scores in 52 and 8%, respectively, at the end of chemo-radiation. Grade 2 toxicity was mainly observed during weeks 4–5, while G3 during weeks 5–6. Median times spent with G2 or G3 toxicity were 23.5 and 14 days. Patients with G3 toxicity were reconverted to a G2 profile in 80% of cases, while those with a G2 score had a decrease to G1 in 58% of cases. Time between maximum acute skin toxicity and complete skin recovery was 30 days. Mean worst pain score evaluated with the Numerical Rating Scale-11 was 6.9 during treatment and 4.5 at the end of chemo-radiotherapy. Hypericum perforatum and neem oil proved to be a safe and effective option in the management of acute skin toxicity in head and neck cancer patients submitted to chemo-radiation with weekly cisplatin. Further studies with a control group and patient-reported outcomes are needed to confirm this hypothesis.
KeywordsHead and neck cancer Concomitant chemo-radiotherapy Skin toxicity Hypericum perforatum Neem oil
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained from all individual participants included in the study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 3.Numico G, Franco P, Cristofano A, Migliaccio F, Spinazzé S, Silvestris N, et al. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol. 2013;85:112–20.CrossRefPubMedGoogle Scholar
- 7.Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, et al. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol. 2015;96:167–82.CrossRefPubMedGoogle Scholar
- 8.Iabichella ML. The use of an extract of Hypericum perforatum and Azadirachta indica in advanced diabetic foot: an unexpected outcome. BMJ Case Rep. 2013; pii:bcr2012007299.Google Scholar
- 11.Franco P, Potenza I, Moretto F, Segantin M, Grosso M, Lombardo A, et al. Hypericum perforatum and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation of chemo-radiation: a single-arm prospective observational study. Radiat Oncol. 2014;9:297.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Franco P, Potenza I, Schena M, Riva G, Pecorari G, Garzino Demo P, et al. Induction chemotherapy and sequential concomitant chemo-radiation in locally advanced head and neck cancers: how induction-phase intensity and treatment breaks may impact on clinical outcomes. Anticancer Res. 2015;35:6247–54.PubMedGoogle Scholar
- 16.Porock D. Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. Eur J Cancer Care (Engl). 2002;11:33–43.Google Scholar